ArticleJACC. Case reports2026
Refractory Malignant Arrhythmia in a 4-Year-Old Child With Short QT Syndrome: Persistence for Hope.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Quinidine: Clinical Lessons From a Child With Short QT Syndrome and Refractory Electrical Storm.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort QT syndrome (SQTS) is a rare cardiac channelopathy and can cause malignant arrhythmia and sudden cardiac arrest. CASE SUMMARY: A 4-year-and-6-month-old girl presented with intermittent convulsions and recurrent ventricular fibrillation requiring multiple electrical cardioversions. Electrocardiogram revealed a QTc interval ranging from 294 to 324 milliseconds and polymorphic ventricular tachycardia. Whole-exome sequencing was performed, which revealed no mutations in ion channel-related genes. Quinidine can prolong the QT interval but failed to reduce the occurrence of premature ventricular arrhythmia. Based on the origin site of premature ventricular contractions and literature reports, verapamil and mexiletine were added to the treatment regimen. After the implantation of implantable cardioverter-defibrillator, intermittent ventricular fibrillations still occurred during the 6-month follow-up. DISCUSSION: When the use of quinidine alone was insufficient to prevent electrical storms, lidocaine test and electrocardiographic characteristics can help guide drug selection. TAKE-HOME MESSAGES: In pediatric SQTS, when high-dose quinidine fails to reduce the risk of sudden death, combination therapy with other antiarrhythmic drugs should be considered. Implantable cardioverter-defibrillator implantation remains the most effective method for preventing sudden death in children with SQTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.